However, this approach proved to be successful also in preclinical studies on TP53 wild-type MM cells most likely because of the occurrence in these cells of G1/S checkpoint inactivation through mechanisms other than direct TP53 mutation [65,66]. Here, TP53 is linked to Miyoshi myopathy.